股票代码：002412 股票简称：汉森制药 湖南汉森制药股份有限公司投资者关系活动记录表 编号：2023-004  特定对象调研 分析师会议 □媒体采访 业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别  现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 红思客资产：杨岌先生 东方财富：王依依女士 及人员姓名 宁波知远：李梁先生 个人投资者：陆金明先生 时间 2023 年10 月7 日（星期六）15:00-17:00 地点 湖南汉森制药股份有限公司一楼会议室 形式 现场参观 董事、副总裁：敖凌松先生 上市公司接待 副总裁、董事会秘书兼财务总监：戴江洪先生 人员姓名 总裁助理兼物料部部长：翟志强先生 证券事务代表：张希雯女士 一、参观文化展厅及车间厂区 由公司副总裁、董事会秘书兼财务总监戴江洪先生、总裁助 理兼物料部部长翟志强先生为大家讲解了公司的发展历程、 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥471,672,377.47, representing a 1.94% increase compared to ¥462,679,892.19 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached ¥90,667,175.74, a 14.94% increase from ¥78,881,640.51 year-on-year[20]. - The net cash flow from operating activities was ¥74,689,978.03, showing a significant increase of 36.42% compared to ¥54,750,153.07 in the previous year[20]. - Basic earnings per share rose to ¥0.1802, up 14.92% from ¥0.1568 in the same period last year[20]. - The total profit for the first half of 2023 reached 100.15 million yuan, reflecting a growth of 12.30% year-on-year[35]. - The net profit after deducting non-recurring gains and losses was ¥86,178,392.83, reflecting a 15.08% increase from ¥74,886,339.66 in the same period last year[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,278,678,252.41, a decrease of 0.54% from ¥2,290,944,050.05 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company decreased by 2.58% to ¥1,845,307,130.40 from ¥1,894,131,702.92 at the end of the previous year[20]. - Cash and cash equivalents decreased by 1.56% to CNY 109,095,075.24, accounting for 4.79% of total assets[47]. - Accounts receivable increased by 0.64% to CNY 245,348,899.32, representing 10.77% of total assets[47]. - Inventory decreased by 0.34% to CNY 237,447,264.62, making up 10.42% of total assets[47]. - Long-term equity investments rose by 2.37% to CNY 831,263,844.38, which is 36.48% of total assets[47]. Cash Flow - The net cash flow from investment activities surged by 1,179.06% to ¥39,884,706.42, compared to ¥3,118,286.37 in the previous year, mainly due to increased cash received from bank wealth management and structured deposits[39]. - The net cash flow from financing activities decreased by 341.62% to -¥140,885,223.13, down from -¥31,901,607.93, primarily due to cash dividends paid amounting to ¥150,960,000.00[39]. - The cash inflow from investment activities for the first half of 2023 was ¥557,593,083.92, a substantial increase from ¥58,124,901.60 in the same period of 2022[140]. - The total cash inflow from investment activities was CNY 451,770,631.74, significantly higher than CNY 10,178,994.00 in the first half of 2022, indicating a substantial increase in investment recovery[143]. Research and Development - The company's R&D investment decreased by 8.18% to ¥21,158,772.35 from ¥23,042,775.48 in the previous year[39]. - Research and development expenses accounted for 4.2% of total revenue, highlighting the company's commitment to innovation[146]. - The company has invested in R&D for new products and generic drug consistency evaluation, which involves high costs and long cycles, posing risks to future profitability[67]. Market Position and Strategy - The company is engaged in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations[29]. - The main product, Si Mo Tang oral solution, is a unique product approved for protection and is included in the national medical insurance catalog[36]. - The company is expanding into the health industry and medical care sectors, diversifying its business operations[29]. - The marketing strategy has been enhanced with a digital approach, improving decision-making and execution efficiency[34]. - The company aims to reduce dependence on single products by diversifying its product portfolio and exploring acquisition opportunities[68]. Corporate Governance and Compliance - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors[78]. - The company has a robust employee rights protection framework, ensuring compliance with labor laws and providing a safe working environment[79]. - The company actively engages in social responsibility initiatives, contributing to local economic development and community welfare[82]. - The company has not implemented any stock incentive plans or employee stock ownership plans during the reporting period[73]. - There were no major litigation or arbitration matters during the reporting period[90]. Future Outlook - The company plans to expand its market presence through new product launches and technological advancements in the upcoming quarters[146]. - Future guidance indicates a projected revenue growth of 20% for the next half of the year, driven by increased demand for its products[146]. - The management provided guidance for the next quarter, expecting a revenue growth of 10% based on current market trends and product pipeline[150]. Environmental and Social Responsibility - The company was recognized as a national-level green factory in March 2023, emphasizing its commitment to environmental protection and sustainable practices[76]. - The company has implemented measures to reduce carbon emissions and promote green office practices[77]. - There were no significant environmental penalties or issues reported during the reporting period[76].

证券代码：002412 证券简称：汉森制药 公告编号：2023-023 湖南汉森制药股份有限公司 第六届董事会第二次会议决议的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性陈 述或者重大遗漏。 一、董事会会议召开情况 《2023 年半年度报告》全文详见 2023 年 8 月 29 日公司指定信息披露网站巨潮 资讯网（www.cninfo.com.cn）；《2023 年半年度报告摘要》（公告编号：2023-025） 同日刊载于《证券时报》《中国证券报》《上海证券报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。 表决结果：7 票同意；0 票弃权；0 票反对。 （二）审议通过了《2023 年半年度募集资金存放与使用情况的专项报告》 公司独立董事对本议案发表了独立意见，《2023 年半年度募集资金存放与使用 情况的专项报告》《独立董事关于公司第六届董事会第二次会议相关事项的独立意见》 详见 2023 年 8 月 29 日巨潮资讯网（www.cninfo.com.cn）。 表决结果：7 票同意；0 票弃权；0 票反对。 - 1 - 三、备查文件 湖南汉森制药股份有限公司 ...

湖南汉森制药股份有限公司 独立董事关于公司第六届董事会第二次会议 相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所股票上市规则》《公司章程》 等有关规定，我们作为湖南汉森制药股份有限公司（以下简称"公司"）独立董事， 现就公司第六届董事会第二次会议审议的议案，发表独立意见如下： 一、关于公司2023年半年度募集资金存放与使用情况的独立意见 经核查，公司2023年半年度募集资金的存放和使用符合中国证监会、深圳证券 交易所关于上市公司募集资金存放和使用的相关规定，符合公司《募集资金使用管 理办法》的有关规定，不存在违规存放和使用募集资金的情形。公司编制的《2023 年半年度募集资金存放与使用情况的专项报告》真实、准确、完整，客观地反映了 公司募集资金存放和使用的实际情况，不存在虚假记录、误导性陈述和重大遗漏。 我们一致同意该议案。 经审阅公司提供的相关资料，基于独立判断的立场，现就截至2023年6月30日， 公司对外担保及关联方资金占用情况，发表以下独立意见： （一）报告期内，公司未发生对外担保事项。 （二）报告期内，公司不存在为控股股东及其关联方提供担保的情况。公司与 其他关联方之间的资金往来均 ...

第六届监事会第二次会议决议的公告 本公司及全体监事保证公告内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 一、监事会会议召开情况 湖南汉森制药股份有限公司（以下简称"公司"）第六届监事会第二次会议 于 2023 年 8 月 25 日在公司一楼会议室召开，本次会议由公司监事会主席刘赛 程女士召集主持，会议通知于 2023 年 8 月 15 日以专人递送、传真及电子邮件 等方式送达给全体监事。应参加会议监事 3 人，实际参加会议监事 3 人。本次 会议采取通讯会议的方式召开。本次会议的召集、召开符合《中华人民共和国公 司法》及《公司章程》的规定。 二、监事会会议审议情况 （一）审议通过了《2023 年半年度报告及摘要》 证券代码：002412 证券简称：汉森制药 公告编号：2023-024 监事会认为：《2023 年半年度报告及摘要》的编制和审核符合法律、法规 的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在虚假记载、 误导性陈述或者重大遗漏。 湖南汉森制药股份有限公司 《2023 年半年度报告》全文详见公司同日披露于指定信息披露网站巨潮资 讯网（www.cninfo.com.cn ...

上市公司2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：湖南汉森制药股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2022年期初占用 | 2023年半年度占 | 2023年半年度占 | 2023年半年度偿 | 2023年半年度期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 会计科目 | 资金余额 | 用累计发生金额 | 用资金的利息 | 还累计发生金额 | 末占用资金余额 | 占用形成原因 | 占用性质 | | | | 司的关联关系 | | | （不含利息） | （如有） | | | | | | 控股股东、实际控制 | 无 | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控 | 无 | | | | | | | | | 非经营性占用 | | 制人及 ...

湖南汉森制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》和深圳证券交易所发布的《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等有关规定，湖南汉森制药股份有限公司（以下简称"公司"或"本公司"） 董事会编制了 2023 年半年度的募集资金存放与使用情况的专项报告，具体如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准湖南汉森制药股份有限公司首次公开发行股票的批 复》（证监许可[2010]509 号）核准，由主承销商宏源证券股份有限公司采用网下询价配售与 网上资金申购定价发行相结合的方式发行人民币普通股（A 股）19,000,000.00 股，发行价格 为每股 35.80 元，向社会公开发行人民币普通股 19,000,000.00 股，募集资金总额为人民币 680,200,000.00 元，扣除此次支付的承销保荐费人民币 1 ...

股票代码：002412 股票简称：汉森制药 | --- | --- | --- | --- | |------------|-----------------------|------------|----------------| | | | | 编号：2023-003 | | | 特定对象调研 | 分析师会议 | | | | □媒体采访 | 业绩说明会 | | | 投资者关系 | | | | | | □新闻发布会 □路演活动 | | | | 活动类别 | | | | | | □现场参观 | | | □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 东吴证券股份有限公司：朱国广先生、李倩女士 时间 2023 年 06 月 20 日（星期二）下午 13:00-14:00 地点 湖南汉森制药股份有限公司二楼会议室 形式 线上会议 董事会秘书兼财务总监：戴江洪先生 上市公司接待 证券事务代表：张希雯女士 人员姓名 互动交流 1．疫情对我们的近几年的影响。 答：医药行业是关系到国计民生的基础性、战略性产业，与 国人身心健康密切相关，在这近三年公司克服疫情反复、行 业内卷加剧、宏观环境不确定性增加等不利影 ...

Group 1: Product Performance - The revenue of the product "Simiao Decoction Oral Liquid" in 2022 was 533 million CNY, representing a year-on-year growth of 8.1% [1] - "Simiao Decoction Oral Liquid" is the only compound gastrointestinal motility traditional Chinese medicine product on the market, enhancing gastrointestinal motility and digestion, with dual regulation effects on constipation and diarrhea [1] Group 2: Future Product Planning - The company plans to increase the promotion of "Simiao Decoction Oral Liquid" to establish brand image and boost sales growth [1] - The company has developed a strategy for intellectual property protection to safeguard exclusive product patents and will continue to invest in technology and processes [2] Group 3: Product Portfolio and Market Strategy - The company has maintained stable growth through acquisitions, forming a product system focused on digestive and cardiovascular medications [2] - The product structure is reasonable and diverse, which helps mitigate operational risks associated with reliance on a single product, enhancing profitability and risk resistance [2] Group 4: Regulatory and Market Positioning - The company is actively monitoring policy changes regarding the inclusion of "Simiao Decoction Oral Liquid" in the essential drug list and aims to meet the evaluation standards for inclusion [2] - The company is developing potential products with local characteristics, such as "Tianma Xingnao Capsule," leveraging regional advantages [2]

股票代码：002412 股票简称：汉森制药 湖南汉森制药股份有限公司投资者关系活动记录表 编号：2023-001 | | □特定对象调研 分析师会议 | | --- | --- | | 投资者关系 | □媒体采访  业绩说明会 | | | □新闻发布会 □路演活动 | | 活动类别 | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 线上参与公司汉森制药 2022 年度网上业绩说明会的投资 | | | 者 | | 及人员姓名 | | | 时间 | 2023 年 05 月 19 日（星期五）下午 15:00-17:00 | | 地点 | "汉森制药投资者关系"微信小程序 | | 上市公司接待 | 董事长兼总裁：刘正清先生 | | | 独立董事：夏劲松先生 | | 人员姓名 | 董事会秘书兼财务总监：戴江洪先生 | | | 1、问：请问贵公司实际控制人是否考虑将南岳生物制药并 | | | 入汉森制药，已达到一同做大做强？另外公司对汉森制药未 | | | 来市值有无想法，能否达到百亿以上规模的市值，谢谢 | | | 答：投资者您好，南岳生物具体情况请您向该公司咨询。公 | ...